Reviewing BioLineRx Ltd. (BLRX)’s and Neuralstem Inc. (NASDAQ:CUR)’s results

BioLineRx Ltd. (NASDAQ:BLRX) and Neuralstem Inc. (NASDAQ:CUR) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLineRx Ltd. N/A 0.00 24.67M -0.23 0.00
Neuralstem Inc. N/A 18.62 7.92M -0.52 0.00

Table 1 demonstrates BioLineRx Ltd. and Neuralstem Inc.’s gross revenue, earnings per share and valuation.


Table 2 provides us BioLineRx Ltd. and Neuralstem Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
BioLineRx Ltd. 0.00% 0% 0%
Neuralstem Inc. 0.00% -123.1% -74.7%

Insider and Institutional Ownership

Roughly 26.75% of BioLineRx Ltd. shares are owned by institutional investors while 16.8% of Neuralstem Inc. are owned by institutional investors. About 3.46% of BioLineRx Ltd.’s share are owned by insiders. Insiders Competitively, owned 13.52% of Neuralstem Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioLineRx Ltd. -2.61% -37.88% -37.87% -55.71% -57.8% -6.24%
Neuralstem Inc. 6.47% 16.4% 0.1% -58.3% -66.18% 59.85%

For the past year BioLineRx Ltd. had bearish trend while Neuralstem Inc. had bullish trend.


On 4 of the 7 factors Neuralstem Inc. beats BioLineRx Ltd.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and GenentechÂ’s Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in ModiÂ’in, Israel.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companyÂ’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.